# New Antipsychotic Strategies: Quetiapine and Risperidone vs. Fluphenazine in Treatment Resistant Schizophrenia

> **NCT00161018** · PHASE3 · COMPLETED · sponsor: **University of Maryland, Baltimore** · enrollment: 150 (—)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Quetiapine, Risperidone, Fluphenazine

## Key facts

- **NCT ID:** NCT00161018
- **Lead sponsor:** University of Maryland, Baltimore
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-11
- **Primary completion:** 2004-11
- **Final completion:** 2004-11
- **Target enrollment:** 150 (—)
- **Last updated:** 2019-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00161018

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00161018, "New Antipsychotic Strategies: Quetiapine and Risperidone vs. Fluphenazine in Treatment Resistant Schizophrenia". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00161018. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*